GL-V9 ameliorates liver fibrosis by inhibiting TGF-β/smad pathway

Exp Cell Res. 2023 Apr 1;425(1):113521. doi: 10.1016/j.yexcr.2023.113521. Epub 2023 Feb 24.

Abstract

Liver fibrosis is a wound-healing response that arises from various aetiologies. Flavonoid compounds have been proved of their anti-liver fibrosis effects. This study aimed to elucidate the protective effect and mechanism of flavonoid compound GL-V9 on CCl4-induced and DDC-induced liver fibrosis. Treatment with GL-V9 alleviated hepatic injury and exhibited a dramatic protection effect of liver fibrosis. Further experiments found that GL-V9 treatment inhibited extracellular matrix (ECM) expression. Activation of hepatic stellate cells (HSCs) is a central driver of fibrosis. GL-V9 could inhibit the activation of HSCs through directly binding to TGFβRI, subsequently inhibit TGF-β/Smad pathway. In conclusion, this study proved that GL-V9 executed a protective effect on liver fibrosis by inhibiting TGF-β/Smad pathway.

Keywords: GL-V9; Liver fibrosis; TGF-β/Smad pathway.

MeSH terms

  • Flavonoids / pharmacology
  • Hepatic Stellate Cells / metabolism
  • Humans
  • Liver Cirrhosis / chemically induced
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / metabolism
  • Signal Transduction*
  • Smad Proteins / metabolism
  • Transforming Growth Factor beta* / metabolism
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Transforming Growth Factor beta
  • Smad Proteins
  • Flavonoids
  • Transforming Growth Factor beta1